{"id":"diclofenac-and-atropine-combination-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Anticholinergic effects (dry mouth, urinary retention, tachycardia)"},{"rate":null,"effect":"Dizziness or blurred vision"},{"rate":null,"effect":"NSAID-related renal or cardiovascular effects"}]},"_chembl":{"chemblId":"CHEMBL139","moleculeType":"Small molecule","molecularWeight":"296.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation and pain. Atropine is an anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing parasympathetic effects such as smooth muscle contraction and secretions. The combination is designed to provide both anti-inflammatory analgesia and antispasmodic effects, potentially useful in conditions involving both pain/inflammation and smooth muscle dysfunction.","oneSentence":"This combination drug reduces inflammation and pain through COX inhibition (diclofenac) while simultaneously blocking muscarinic acetylcholine receptors (atropine) to modulate parasympathetic activity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:22.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Abdominal pain and cramping associated with gastrointestinal disorders"},{"name":"Biliary or renal colic with antispasmodic benefit"}]},"trialDetails":[{"nctId":"NCT02194088","phase":"PHASE3","title":"Combined Medication for Improved Analgesia in Superficial Pain","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-04","conditions":"Pain","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Analgesic drug","Combination drug","Test drug","Diclofenac and atropine","Atropine and diclofenac"],"phase":"phase_3","status":"active","brandName":"Diclofenac and Atropine combination drug","genericName":"Diclofenac and Atropine combination drug","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug reduces inflammation and pain through COX inhibition (diclofenac) while simultaneously blocking muscarinic acetylcholine receptors (atropine) to modulate parasympathetic activity. Used for Abdominal pain and cramping associated with gastrointestinal disorders, Biliary or renal colic with antispasmodic benefit.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}